OT: Stock and Investment Talk
- Thread starter RU-05
- Start date
Sounds like no more rate increases. Doves taking over the Fed with the newer members:
Top Fed officials nod to higher bond yields as cause for caution on rates
Top Fed officials nod to higher bond yields as cause for caution on rates
Steve Weiss pumping MSFT as THE ultimate winner in the AI arms race…over NVDA. The AI HODLers are making themselves known.
Their OpenAI investment is likely worth around $40-45 billion right now. They’re off to a good start
They’re planning on making their own chips. They’re going after that 100 p/e multiple…😂
Price target = $1,000/share can’t be far behind.
Both will do very well. One on hardware, one on software and applications. Buy both and hold long!
Greg Mannarino posted this morning that the reason for this war is the liquidity crisis:They had to get the war machine cranked up in order to resume counterfeiting .
Forgot to mention, yesterday I bought a ton of TPST call options just out of the money. Had a hunch.
😁
MSFT and Activision deal finally approved by all regulators:
Still eyeing BLUE and CRSP for December PDUFA dates, both will likely get approvals for sickle cell anemia gene therapies. If interested, start looking for a dip to buy or wait for a short-term call option next month.
Also been tracking CLRB (Cellectar Biosciences). Super small biotech working on technology to make radiation therapy more targeted and effective. Next round of data to report in "Q4", so pretty soon. I'm looking for a nice entry point. Why CLRB? A few weeks ago, they did a new round of financing. The investment shop that's supporting CLRB is well-known and normally right on their bets. If they are in, I will jump in with a small position and see what happens.
Also been tracking CLRB (Cellectar Biosciences). Super small biotech working on technology to make radiation therapy more targeted and effective. Next round of data to report in "Q4", so pretty soon. I'm looking for a nice entry point. Why CLRB? A few weeks ago, they did a new round of financing. The investment shop that's supporting CLRB is well-known and normally right on their bets. If they are in, I will jump in with a small position and see what happens.
PLTR and NU charts looking like they are ready to break out. Damn TK, you are getting killed in the other thread you started. I cant believe you gave up on our team.
The only way to survive as a RU football is to expect the worst and be pleasantly surprised if something good happens. LOL!
Speaking of NU/crypto, the SEC declined to appeal the court ruling on Greyscale. Spot ETF finally coming soon? What's the best options play? MARA, RIOT, or HUT?
I've been seeing articles lately about LLY NVO weight loss drugs having rippling effects in other industries like food/snack makers, medical device companies, airlines etc.. It is a popular and very in demand drug but I still wonder about how much of an impact it can have into the whole economy/country. At the moment, it's not cheap either and not covered for weight loss. It's been a boon for NVO and LLY though.
markets.businessinsider.com
The stock market is getting Ozempic'ed
The collective shedding of hundreds of millions of pounds via GLP-1 drugs is poised reshuffle trillions of dollars in the stock market and economy.
markets.businessinsider.com
Hmm. I understand that Ozempic et al will have direct health benefits, so DaVita being impacted makes sense. However, I am dubious that nutritional behavior will change that much. It would be great for the nation if this happens, but normally a "magic pill" is viewed as an easy way to have your cake and eat it too. Pun intended. LOL!I've been seeing articles lately about LLY NVO weight loss drugs having rippling effects in other industries like food/snack makers, medical device companies, airlines etc.. It is a popular and very in demand drug but I still wonder about how much of an impact it can have into the whole economy/country. At the moment, it's not cheap either and not covered for weight loss. It's been a boon for NVO and LLY though.
The stock market is getting Ozempic'ed
The collective shedding of hundreds of millions of pounds via GLP-1 drugs is poised reshuffle trillions of dollars in the stock market and economy.
Well its mechanism of action isn't having cake at all. Some of the side effects like blockage and digestive paralysis stems from that. I believe it works because food moves more slowly through the system taking away feelings of hunger and appetite. So you don't want have your cake and eat it too, you just don't want the cake.
The thought it is with if so many people don't have the same desire/cravings for food it will affect the food/snack industry, lower demand for medical devices/procedures, save airlines money on fuel consumption because of reduced weight load, etc..
I kind of find that thinking to be utopic and hyperbole. The drugs are in massive demand and popular but will it get to the point where it has such rippling effects? I'm someone who will do anything to avoid drugs and I'd think there must be others who have similar thinking. It's also not cheap. It's a big money maker for LLY and NVO but is it so big that it will impact other industries? I'm skeptical.
True on the drugs. I lived through the first round of obesity drugs that supposedly worked in the same way.....but consumer behavior never changed. That was 20 years ago and surely these products are way more advanced. Only time will tell if the stock market is overreacting or not.
So short Krispy Kreme? :)
“Chip maker and AI king” MSFT has settled in at around $330/share b4 earnings release next week. What did Fibonacci have to say about AI again? I mean who doesn’t love 1,000 year old mathematicians from Pisa!
DIS has so far bounced off that that support level and held. Deep pockets from big tech and distribution through telcom can be quite helpful. I think they were looking to sell 10% but sounds like that figure is malleable.
From the article:
Disney is aiming to sell a stake in ESPN to both a digital company like Apple and a mobile platform like Verizon, The New York Post reported, without citing any sources.
The goal would be to leverage its sports assets with the best distribution channels, the Post reported. A deal with a digital platform like Apple would mean an ESPN app could be pre-installed on new iPhones, iPads and Macs, though that could also be done with companies like Google or Amazon. Meanwhile, a deal with a mobile platform such as T-Mobile or Verizon would make ESPN available on phones that use their service networks.
themessenger.com
From the article:
Disney is aiming to sell a stake in ESPN to both a digital company like Apple and a mobile platform like Verizon, The New York Post reported, without citing any sources.
The goal would be to leverage its sports assets with the best distribution channels, the Post reported. A deal with a digital platform like Apple would mean an ESPN app could be pre-installed on new iPhones, iPads and Macs, though that could also be done with companies like Google or Amazon. Meanwhile, a deal with a mobile platform such as T-Mobile or Verizon would make ESPN available on phones that use their service networks.
Disney Wants Both Digital and Mobile Partners for ESPN: Report
Disney is said to be looking for two investors to help move ESPN into the digital age
themessenger.com
Makes sense, bought DIS at $79.5'ish. So far so good:DIS has so far bounced off that that support level and held. Deep pockets from big tech and distribution through telcom can be quite helpful. I think they were looking to sell 10% but sounds like that figure is malleable.
From the article:
Disney is aiming to sell a stake in ESPN to both a digital company like Apple and a mobile platform like Verizon, The New York Post reported, without citing any sources.
The goal would be to leverage its sports assets with the best distribution channels, the Post reported. A deal with a digital platform like Apple would mean an ESPN app could be pre-installed on new iPhones, iPads and Macs, though that could also be done with companies like Google or Amazon. Meanwhile, a deal with a mobile platform such as T-Mobile or Verizon would make ESPN available on phones that use their service networks.
Disney Wants Both Digital and Mobile Partners for ESPN: Report
Disney is said to be looking for two investors to help move ESPN into the digital age
Good day for LULU:
Lululemon shares hit nearly two-year high on S&P 500 inclusion
Lululemon shares hit nearly two-year high on S&P 500 inclusion
Quick update for those keeping track:
PDUFA for CRSP is December 8
PDUFA for BLUE is December 20
The FDA announced that they will not meet for AdComs during the review process for either sickle cell gene therapy. This is normally a telltale sign that approval is highly likely. I believe BLUE has the better product based on clinical data and will get the bigger bounce on approval (and I think it will bounce even when/if CRSP is approved).
I had a nice day from INDI. Up 18% on Q3 rev guidance.
Granted the thing is bouncing off all time lows, and I'm still well in the red.
But I did add some last week.
MS not loving BLUE. Price target of $3.
"Although Bluebird Bio has 2 approved gene therapies with a potential for a third in 2023, we think uptake will be modest given challenging market dynamics. The sickle cell disease space is increasingly competitive, and cerebral adrenoleukodystrophy is a very small market. For Zynteglo in beta-thalassemia, securing reimbursement can include restrictions by payors that are not on the drug label, and the company will reimburse up to 80% of Zynteglo's cost if a patient is not transfusion dependent within 2 years."
I agree with MS on the current outlook on BLUE. Zynteglo and Skysona are not going to be windfalls for the company, but sickle cell anemia is the holy grail for LVV gene therapies. Based on the data and FDA process to date, all signs point to approval and this should pop the stock 50-100% (which is common for biotech).
I am not a long-term holder of BLUE, but I think this possible bounce is perfect for a short term options play. Same for Crispr.
Any update on how long to profitability? Same for WOLF. Both look promising, but no rush.
I am surprised you chose BLUE over CRSP. CRSP is in a much better financial situation.
Can I ask you a question... If you are confident that BLUE can double from here, why aren't you buying this stock hand over fist? You are starting to sound like these so called pundits who don't put their money where their mouth.
A few things. I am not making any long-term judgments on CRSP or BLUE. I am just looking for a "tradeable event". I believe BLUE is set-up for a bigger pop due to:
1. Much smaller market cap
2. Sickle cell approval means more to BLUE than CRSP
3. BLUE will likely get a pop for a CRSP approval and then another pop with their approval
4. BLUE's sickle cell GTx data is better, so I believe their FDA approval is even more likely than CRSP
To be clear, I think both PDUFA events are great for a short-term call option play. BLUE might pop more, but likely give most of the gains back over the next week or so. The timing for such calls should be mid-late November.
BLUE already has 2 product approvals, so their challenge is to commercialize and find patients. CRSP is still working on their basic platform and science. They may be better funded right now, but still have no approvals.
Big banks doing well with earnings so far:
www.cnbc.com
Bank of America tops profit estimates on better-than-expected interest income
Bank of America was supposed to be one of the big beneficiaries of higher interest rates. Instead, the stock has been the worst performer among peers this year.
I didn't see anything in yesterdays news about earnings.
The earnings estimates on E-Trade, a consensus of 6 analysts(which I think is all the wall street analysts covering the company), is for positive earnings in q1 of 2024, and .17 per share for the year. The past 8 qtr's it has been pretty much in line with estimates, give or take a penny. Nothing beyond that currently, but positive next year is pretty encouraging.
If nothing else it looks like it's poised for a continuance of this bounce. Potential resistance at $8.
